Company · GILD
Gilead Sciences
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
38
33 still marketed
Novel approvals
21
Approvals since 2021
45
Originals and new uses
Phase 3 trials
219
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Sunlenca new use Aug 27, 2026
- Bixlenvo approved Priority reviewAug 27, 2026
- Sunlenca new use Aug 27, 2026
- Bixlenvo Sunlenca Starter Pack (Copackaged) approved Aug 27, 2026
- Trodelvy new use Jun 24, 2026
- Trodelvy new use Jun 24, 2026
- Hepcludex approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 22, 2026
- Biktarvy new use OrphanJul 30, 2025
- Tybost new use OrphanJun 20, 2025
- Tybost new use OrphanJun 20, 2025
Drugs in development (26)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- AmrubicinJapan onlyPhase 34 trials
Gilead Sciences · Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- ISLPhase 33 trials
Merck & Co. · HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- QuemliclustatPhase 33 trials
Arcus Biosciences, Inc. · Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Non-Small Cell Lung Cancer, Gastrointestinal Tract Malignancies
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- VinflunineJavlorPhase 33 trials
Merck & Co. · Bladder Cancer, Urothelial Cancer, Locally Advanced or Metastatic Unresectable Urothelial Cancer
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- KITE-753Phase 32 trials
Gilead Sciences · Relapsed or Refractory Large B-cell Lymphoma, Relapsed and/or Refractory B-cell Lymphoma
- OBRPhase 32 trials
Gilead Sciences · HIV-1-infection
- PTM FPhase 32 trials
Gilead Sciences · Pre-Exposure Prophylaxis of HIV Infection
- PTM LENPhase 32 trials
Gilead Sciences · Pre-Exposure Prophylaxis of HIV Infection
- Sub-cutaneous LenacapavirPhase 31 trial
Gilead Sciences · Pre-Exposure Prophylaxis of HIV Infection
- AB928Etrumadenant, ETRUMAPhase 24 trials
Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- TUB-040Phase 24 trials
Gilead Sciences · Ovarian Cancer, Non-small Cell Lung Cancer, Uterine Endometrial Cancer
- TMB-365TMB-380, VRC07523LSPhase 23 trials
TaiMed Biologics Inc. · HIV-1-infection, HIV -1 Infection
- DenikitugGS-1811, DENPhase 22 trials
Gilead Sciences · Advanced Microsatellite Stable Colorectal Cancer, HER2-negative, Gastroesophageal Junction
- CAP256V2LSPhase 21 trial
Gilead Sciences · HIV-1-infection
- GS-1179Phase 21 trial
Gilead Sciences · HSV-2 Infection
- GS-4321Phase 21 trial
Gilead Sciences · Chronic Hepatitis Delta
- KITE-363Phase 21 trial
Gilead Sciences · Relapsed and/or Refractory B-cell Lymphoma
Recruiting Phase 3 trials
Largest first.
Gilead SciencesGilead Sciences (GILD)
NCT05633654 · 1,514 participants (planned) · Start Dec 12, 2022 · Primary completion Jun 2027
Drug: Sacituzumab govitecan-hziy (SG); Pembrolizumab and 1 more · For: Triple Negative Breast Cancer
Sites: Birmingham, Alabama; Huntsville, Alabama; Glendale, Arizona · 378 sites in all
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07708727 · 700 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2030
Drug: GS-3242 Tablet; GS-3242 Injection and 3 more · For: HIV-1-infection
Sites: Torrance, California; New Haven, Connecticut; Ft. Pierce, Florida · 21 sites in all
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT06801834 · 695 participants (planned) · Start Apr 4, 2025 · Primary completion Oct 2029
Drug: Sacituzumab Govitecan (SG); Topotecan and 2 more · For: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sites: Anchorage, Alaska; Hot Springs, Arkansas; Anaheim, California · 219 sites in all
- Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07683000 · 590 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 3 more · For: HIV-1-infection
Sites: Berkeley, Michigan; Annandale, Virginia
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT06051617 · 402 participants (planned) · Start Sep 7, 2023 · Primary completion Aug 2030
Drug: Seladelpar; Placebo · For: Primary Biliary Cholangitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Lancaster, California · 218 sites in all
Marketed drugs (33)
Newest FDA action first.
- Sunlenca Lenacapavir Sodium · 2022
- Bixlenvo Bictegravir Sodium, Lenacapavir Sodium · 2026
- Sunlenca Lenacapavir Sodium · 2022
- Bixlenvo Sunlenca Starter Pack (Copackaged) Bictegravir Sodium, Lenacapavir Sodium, Lenacapavir Sodium · 2026
- Veklury Remdesivir · 2020
- Trodelvy Sacituzumab Govitecan-Hziy · 2020
- Hepcludex Bulevirtide-Gmod · 2026
- Biktarvy Bictegravir Sodium, Emtricitabine, Tenofovir Alafenamide Fumarate · 2018
- Livdelzi Seladelpar Lysine · 2024
- Descovy Emtricitabine, Tenofovir Alafenamide Fumarate · 2016
- Yeztugo Lenacapavir Sodium · 2025
- Yeztugo Lenacapavir, Lenacapavir Sodium · 2025
- Letairis Ambrisentan · 2007
- Odefsey Emtricitabine, Rilpivirine Hydrochloride, Tenofovir Alafenamide Fumarate · 2016
- Sovaldi Sofosbuvir · 2013
- Sovaldi Sofosbuvir · 2019
- Harvoni Ledipasvir, Sofosbuvir · 2014
- Harvoni Ledipasvir, Sofosbuvir · 2019
- Truvada Emtricitabine, Tenofovir Disoproxil Fumarate · 2004
- Vemlidy Tenofovir Alafenamide Fumarate · 2016
- Epclusa Sofosbuvir, Velpatasvir · 2016
- Zydelig Idelalisib · 2014
- Epclusa Sofosbuvir, Velpatasvir · 2021
- Genvoya Cobicistat, Elvitegravir, Emtricitabine, Tenofovir Alafenamide Fumarate · 2015
- Stribild Cobicistat, Elvitegravir, Emtricitabine, Tenofovir Disoproxil Fumarate · 2012
- Complera Emtricitabine, Rilpivirine Hydrochloride, Tenofovir Disoproxil Fumarate · 2011
- Cayston Aztreonam · 2010
- Vosevi Sofosbuvir, Velpatasvir, Voxilaprevir · 2017
- Viread Tenofovir Disoproxil Fumarate · 2001
- Viread Tenofovir Disoproxil Fumarate · 2012
- Emtriva Emtricitabine · 2003
- Emtriva Emtricitabine · 2005
- Zydelig Idelalisib · 2014
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.